查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425010

急性淋巴母细胞白血病治疗市场，按应用、按药物、按国家和地区划分 - 2023-2030 年行业分析、市场规模、市场份额和预测

Acute Lymphoblastic Leukemia Therapeutics Market, By Application, By Drug, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 277 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年，急性淋巴母细胞白血病治疗市场规模为37.942亿美元，2023年至2030年CAGR为5.7%。

急性淋巴母细胞白血病治疗市场-市场动态

急性淋巴细胞白血病发病率的增加和全球骨髓活检的激增预计将推动市场需求

由于急性淋巴细胞白血病发病率的增加和全球骨髓活检的激增，该市场正在成长。此外，对白血病研究的投资增加以及人们对标靶治疗的认识不断提高正在推动市场扩张。然而，严格的监管审批和不良药物副作用带来了挑战。关键治疗药物的专利到期和治疗成本上升也限制了市场成长。儘管如此，不断增加的临床试验和新产品批准为新兴和已开发市场提供了机会。

急性淋巴母细胞白血病治疗市场 - 关键见解

根据我们的研究分析师分享的分析，全球急性淋巴母细胞白血病治疗市场预计在预测期内（2023-2030）每年将以 5.7% 左右的CAGR成长

由于急性淋巴母细胞白血病发病率增加和全球骨髓活检激增，预计急性淋巴性白血病治疗市场将以显着速度成长

根据应用，儿科领域预计将在 2022 年显示最大的市场份额

基于药物，Hyper-CVAD 疗法是 2022 年的领先细分市场

按地区划分，北美是 2022 年的主要收入来源

急性淋巴母细胞白血病治疗市场-細項分析：

全球急性淋巴母细胞白血病治疗市场根据应用、药物和地区进行细分。

根据应用，市场分为两个部分：儿科和成人。儿科部门产生了最高的收入，预计在整个预测期内将保持领先地位。这主要归因于儿科族群中急性淋巴球/淋巴球白血病的发生率增加。急性淋巴性/淋巴性白血病是儿科族群中最常见的癌症类型之一。此外，儿科患者在急性淋巴细胞/淋巴细胞白血病治疗中表现出更高的成功率，进一步巩固了该领域的主导地位。

市场依药物分为六个部分：Hyper-CVAD 方案、Linker 方案、核苷代谢抑制剂（如 Clolar 和 Nelarabine）、标靶药物和免疫疗法、CALGB 8811 方案和 Oncaspar。其中，Hyper-CVAD 方案由于其在 ALL 治疗中的广泛应用，将在 2022 年成为急性淋巴细胞/淋巴细胞白血病治疗市场的主导者。 Hyper-CVAD 方案被广泛认为是急性淋巴性/淋巴球白血病最常用的治疗选择之一。

急性淋巴母细胞白血病治疗市场-地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

急性淋巴母细胞白血病治疗市场-竞争格局：

急性淋巴母细胞白血病治疗领域的公司正在积极从事研究和开发，以推进治疗选择。他们投资于发现针对 ALL 特定方面的新药和疗法，旨在提高疗效并减少副作用。与医疗机构和学术研究中心的合作促进了临床试验和创新疗法的发展。我们也致力于提高这些治疗的可近性和可负担性，特别是在新兴市场。此外，公司优先考虑监管批准并遵守严格的品质标准，以确保患者安全。总体而言，他们的目标是继续发展 ALL 疗法的前景，为与这种具有挑战性的疾病作斗争的患者带来希望和更好的结果。

最近的发展：

2023年5月，总部位于美国和爱尔兰的製药公司Shorla Oncology与生命科学领域领先的商业化服务供应商EVERSANA合作，正式启动奈拉滨注射液的商业上市。该药物旨在治疗未出现阳性反应的成人和一岁及以上儿童患者的 T 细胞急性淋巴母细胞白血病(T-ALL) 和 T 细胞淋巴细胞淋巴瘤 (T-LBL)，或在至少两种化疗方案治疗后出现復发。

目录

第一章：急性淋巴母细胞白血病治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 急性淋巴母细胞白血病治疗市场片段（依应用）
    • 急性淋巴母细胞白血病治疗市场片段（按药物）
    • 按国家/地区分類的急性淋巴母细胞白血病治疗市场片段
    • 按地区分類的急性淋巴母细胞白血病治疗市场片段
  • 竞争洞察

第 3 章：急性淋巴母细胞白血病治疗主要市场趋势

  • 急性淋巴母细胞白血病治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 急性淋巴母细胞白血病治疗市场限制
    • 市场限制影响分析
  • 急性淋巴母细胞白血病治疗市场机会
  • 急性淋巴母细胞白血病治疗市场未来趋势

第 4 章：急性淋巴母细胞白血病治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：急性淋巴母细胞白血病治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：急性淋巴母细胞白血病治疗市场格局

  • 2022 年急性淋巴母细胞白血病治疗市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：急性淋巴母细胞白血病治疗市场 -按应用

  • 概述
    • 按应用的细分市场占有率分析
    • 儿科
    • 成年人

第 8 章：急性淋巴母细胞白血病治疗市场 - 按药物

  • 概述
    • 按药物分類的细分市场份额分析
    • 超级 CVAD 方案
    • 连接器方案
    • 核苷代谢抑制剂（Clolar 和 Nelarabine）
    • 标靶药物和免疫治疗
    • CALGB 8811 方案
    • 翁卡斯帕

第 9 章：急性淋巴母细胞白血病治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美急性淋巴母细胞白血病治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按应用）
    • 北美市场规模和预测（按药物）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲急性淋巴母细胞白血病治疗药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按应用）
    • 欧洲市场规模与预测（按药品）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区急性淋巴母细胞白血病治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按应用）
    • 亚太地区药物市场规模与预测
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲急性淋巴母细胞白血病治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按应用）
    • 拉丁美洲市场规模与预测（按药品）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲急性淋巴母细胞白血病治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按应用）
    • 中东和非洲市场规模及预测（按药品）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析-急性淋巴母细胞白血病治疗产业

  • 竞争仪表板
  • 公司简介
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Erytech Pharma, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Kite Pharma, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Spectrum

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2210

REPORT HIGHLIGHT

Acute Lymphoblastic Leukemia Therapeutics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Acute Lymphoblastic Leukemia Therapeutics Market- Market Dynamics

Increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies is expected to propel the market demand

The market is witnessing growth due to the increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies. Additionally, heightened investments in leukemia research and growing awareness of targeted therapies among the population are driving market expansion. However, stringent regulatory approvals and adverse drug side effects pose challenges. Patent expirations of key treatment drugs and elevated therapy costs also limit market growth. Nonetheless, increasing clinical trials and new product approvals offer opportunities in emerging and developed markets.

Acute Lymphoblastic Leukemia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Acute Lymphoblastic Leukemia Therapeutics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Acute Lymphoblastic Leukemia Therapeutics Market is projected to grow at a significant rate driven by increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies

Based on Application, the pediatrics segment was predicted to show maximum market share in the year 2022

Based on Drug, Hyper -CVAD Regimen was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Acute Lymphoblastic Leukemia Therapeutics Market- Segmentation Analysis:

The Global Acute Lymphoblastic Leukemia Therapeutics Market is segmented on the basis of Application, By Drug, and Region.

Based on the application, the market is divided into two segments: pediatrics and adults. The pediatrics segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. This is primarily attributed to the elevated incidence of acute lymphocytic/lymphoblastic leukemia among the pediatric population. Acute lymphocytic/lymphoblastic leukemia ranks as one of the most prevalent cancer types in the pediatric demographic. Furthermore, pediatric patients exhibit a higher success rate in acute lymphocytic/lymphoblastic leukemia treatments, further solidifying the segment's dominance.

The market is categorized by Drug into six segments: Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (such as Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Among these, the Hyper-CVAD Regimen emerged as the dominant player in the acute lymphocytic/lymphoblastic leukemia therapeutics market in 2022 due to its extensive utilization in ALL treatment. The Hyper-CVAD Regimen is widely recognized as one of the most frequently employed therapeutic options for acute lymphocytic/lymphoblastic leukemia.

Acute Lymphoblastic Leukemia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Acute Lymphoblastic Leukemia Therapeutics Market- Competitive Landscape:

Companies in the Acute Lymphoblastic Leukemia therapeutics sector are actively engaged in research and development to advance treatment options. They invest in the discovery of novel drugs and therapies that target specific aspects of ALL, aiming for improved efficacy and reduced side effects. Collaborations with healthcare institutions and academic research centers facilitate clinical trials and the development of innovative treatments. Efforts are also directed towards enhancing the accessibility and affordability of these treatments, particularly in emerging markets. Furthermore, companies prioritize regulatory approvals and adherence to stringent quality standards to ensure patient safety. Overall, their goal is to continue evolving the landscape of ALL therapeutics, offering hope and better outcomes for patients battling this challenging disease.

Recent Developments:

In May 2023, Shorla Oncology, a pharmaceutical company based in the United States and Ireland, in collaboration with EVERSANA, a leading provider of commercialization services for the life science sector, officially initiated the commercial release of Nelarabine Injection. This drug is intended for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in both adult and pediatric patients aged one year and older who have not experienced a positive response to, or have experienced relapse following treatment with, a minimum of two chemotherapy regimens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET KEY PLAYERS

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Erytech Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Kite Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Spectrum

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY APPLICATION

  • Pediatrics
  • Adults

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

  • Hyper-CVAD Regimen
  • Linker Regimen
  • Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
  • Targeted Drugs & Immunotherapy
  • CALGB 8811 Regimen
  • Oncaspa

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Acute Lymphoblastic Leukemia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Application
    • 2.1.2. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Drug
    • 2.1.3. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Country
    • 2.1.4. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Acute Lymphoblastic Leukemia Therapeutics Key Market Trends

  • 3.1. Acute Lymphoblastic Leukemia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Acute Lymphoblastic Leukemia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Acute Lymphoblastic Leukemia Therapeutics Market Opportunities
  • 3.4. Acute Lymphoblastic Leukemia Therapeutics Market Future Trends

4. Acute Lymphoblastic Leukemia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Acute Lymphoblastic Leukemia Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Acute Lymphoblastic Leukemia Therapeutics Market Landscape

  • 6.1. Acute Lymphoblastic Leukemia Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Acute Lymphoblastic Leukemia Therapeutics Market - By Application

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 7.1.2. Pediatrics
    • 7.1.3. Adults

8. Acute Lymphoblastic Leukemia Therapeutics Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
    • 8.1.2. Hyper-CVAD Regimen
    • 8.1.3. Linker Regimen
    • 8.1.4. Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
    • 8.1.5. Targeted Drugs & Immunotherapy
    • 8.1.6. CALGB 8811 Regimen
    • 8.1.7. Oncaspa

9. Acute Lymphoblastic Leukemia Therapeutics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Acute Lymphoblastic Leukemia Therapeutics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Amgen, Inc.
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Celgene Corporation
    • 10.2.4. Erytech Pharma, Inc.
    • 10.2.5. F. Hoffmann-La Roche Ltd.
    • 10.2.6. Kite Pharma, Inc.
    • 10.2.7. Novartis AG
    • 10.2.8. Pfizer Inc.
    • 10.2.9. Sanofi
    • 10.2.10. Spectrum

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Application 2018-2030 (USD Million)
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Drug Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Drug 2018-2030 (USD Million)
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)

List of Figures

  • FIGURE Acute Lymphoblastic Leukemia Therapeutics Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Application segment market share analysis, 2022 & 2030
  • FIGURE Application segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drug segment market share analysis, 2022 & 2030
  • FIGURE Drug segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Europe Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Germany Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE India Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Brazil Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Saudi Arabia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)